I have a hard time seeing how the current SP and O

I have a hard time seeing how the current SP and OTC enters into the partnership/licensing deal. We have quite a bit of data to show this is a combo and mono drug. Any partner is going strait to the trial data to see what his drug is and what it is worth. The ugly financing that it takes to get to this point is widely accepted because that is typical in biotech. Value of this drug is as it sits, not the packaging. I am concerned that mgmt really does not know how to negotiate and/or the offers are very complicated in terms of what the partnership includes and excludes. How can a company license a drug for a specific indication and then see that another partner steps in to license a different indication? Where is the line? what is being paid and when? what are the triggers for payment prior to FDA appoval etc..